Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: resembling (46)

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This protocol was developed in response
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Everolimus-Lenvatinib

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological diagnosis of inoperable locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf

Lenalidomide-RituximabIV/SC

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV/SC) There are multiple versions of this protocol in use. Please ensure you have the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-RituximabIVSC.pdf

Lenalidomide-Rituximab IV

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV) There are multiple versions of this protocol in use. Please ensure you have the correct
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Rituximab-IV.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Bendamustine-Obinutuzumab

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

BEACOPP escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP Escalated) Regimen • Lymphoma – BEACOPP Escalated -Bleomycin-Cyclophosphamide-DoxorubicinEtoposide-Prednisolone-Procarbazine-Vincristine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

BEACOPP 14

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP-14) Regimen • Lymphoma – BEACOPP-14-Bleomycin-Cyclophosphamide-Doxorubicin-EtoposidePrednisolone-Procarbazine-Vincristine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-14.pdf

701 to 710 of 761

Previous … 69 70 71 72 73 … Next